Yajing Chen Sells 5,280 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 5,280 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.89, for a total value of $189,499.20. Following the transaction, the chief financial officer now directly owns 25,471 shares in the company, valued at approximately $914,154.19. This represents a 17.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Yajing Chen also recently made the following trade(s):

• On Friday, April 4th, Yajing Chen sold 924 shares of Zai Lab stock. The shares were sold at an average price of $33.11, for a total transaction of $30,593.64.

Zai Lab Trading Down 6.0 %

Shares of ZLAB stock traded down $1.74 during mid-day trading on Tuesday, reaching $27.07. The stock had a trading volume of 2,122,402 shares, compared to its average volume of 791,899. The stock's 50-day moving average price is $32.76 and its two-hundred day moving average price is $28.96. The firm has a market capitalization of $2.97 billion, a PE ratio of -9.77 and a beta of 1.09. Zai Lab Limited has a 52-week low of $13.48 and a 52-week high of $39.77.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The business had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. On average, equities research analysts forecast that Zai Lab Limited will post -2.58 earnings per share for the current year.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th. Scotiabank assumed coverage on Zai Lab in a research note on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, March 13th. Finally, Bank of America restated a "neutral" rating and set a $36.10 price target (up from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

Institutional Trading of Zai Lab

Several large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Zai Lab in the 4th quarter worth about $29,000. Public Employees Retirement System of Ohio lifted its holdings in Zai Lab by 20.8% in the fourth quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company's stock worth $484,000 after buying an additional 3,179 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Zai Lab by 2.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock valued at $1,496,000 after acquiring an additional 1,200 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Zai Lab by 9.4% during the 4th quarter. Woodline Partners LP now owns 1,759,797 shares of the company's stock worth $46,089,000 after acquiring an additional 151,835 shares during the period. Finally, Vestal Point Capital LP bought a new position in shares of Zai Lab in the 4th quarter worth approximately $7,857,000. Institutional investors own 41.65% of the company's stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.